clinical trial · NCT06553885
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 40
Metastatic Colorectal CancerHepatocellular CarcinomaEnfortumab Vedotin
brief summary
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
started
Apr 1, 2025
primary completion
Sep 1, 2029
completion
Sep 1, 2029
last updated
Apr 1, 2026
official title
A Phase II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol